Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Salil Sethi

Interventional Cardiology Sun City West, AZ Medical Doctor

NPI 1164665477 CMS profile 1401490

14502 W Meeker Blvd, Sun City West, AZ 85375

Open in the dashboard

General payments

$43,610

475 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Salil Sethi of Sun City West, AZ is reported in the CMS Open Payments database as having received $43,610 across 475 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $9,633 69
2024 General $14,174 72
2023 General $6,054 60
2022 General $8,448 81
2021 General $1,484 41
2020 General $1,071 57
2019 General $2,746 95

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Salil Sethi
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Salil Sethi were reported at $9,633. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Salil Sethi Interventional Cardiology median Middle half National median
2019 $2,746 $1,097 $329–$3,048 $163
2020 $1,071 $473 $161–$1,480 $114
2021 $1,484 $677 $233–$1,827 $132
2022 $8,448 $978 $333–$2,724 $149
2023 $6,054 $1,136 $382–$2,986 $160
2024 $14,174 $1,181 $395–$3,326 $164
2025 $9,633 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Edwards Lifesciences Corporation $21,457 55 payments
  2. Medtronic, Inc. $3,845 42 payments
  3. Penumbra, Inc. $3,401 17 payments
  4. Cardiovascular Systems Inc. $2,683 6 payments
  5. Abiomed $1,793 28 payments
  6. Abbott Laboratories $1,768 30 payments
  7. Cordis US Corp. $1,197 4 payments
  8. Boston Scientific Corporation $803 20 payments
  9. Amgen Inc. $715 23 payments
  10. Janssen Pharmaceuticals, Inc $582 62 payments
  11. Other $5,366 188 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $18,255 437 payments
  2. Consulting Fee $14,840 9 payments
  3. Travel and Lodging $6,309 21 payments
  4. Compensation for serving as faculty or as a speaker for a medical education program $2,325 1 payment
  5. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $1,590 1 payment
  6. Education $292 6 payments
Products named General payments · program years 2019–2025
  1. Edwards SAPIEN 3 Ultra Transcatheter Heart Valve $12,207 13 payments
  2. SAPIEN 3 Ultra RESILIA $5,600 23 payments
  3. Diamondback Peripheral $2,683 6 payments
  4. Indigo System $2,121 15 payments
  5. EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) $1,957 14 payments
  6. Edwards SAPIEN 3 Transcatheter Heart Valve $1,692 5 payments
  7. IN.PACT Admiral $1,548 14 payments
  8. MITRACLIP $1,474 15 payments
  9. RUBY Coil $1,279 2 payments
  10. Impella $1,261 15 payments
  11. Other $13,110 393 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 55 drugs

Part D claims

6,956

Median for Interventional Cardiology: 2,236

Drug cost

$1,040,144

Median for Interventional Cardiology: $380,412

Branded share of claims

27.8%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 368 $482,301
Entresto Sacubitril/Valsartan Brand 86 $137,271
Xarelto Rivaroxaban Brand 104 $115,707
Brilinta Ticagrelor Brand 121 $106,050
Repatha Sureclick Evolocumab Brand 46 $36,449
Jardiance Empagliflozin Brand 20 $25,344
Repatha Pushtronex Evolocumab Brand 16 $23,694
Multaq Dronedarone Hcl Brand 26 $16,586
Praluent Pen Alirocumab Brand 12 $12,801
Metoprolol Succinate Generic 816 $9,466

The 10 drugs with the highest cost, of 55 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 121 billing codes

Paid by Medicare

$586,514

Of which drugs: $1,828

Medicare patients

1,089

Average age 76

Services billed

8,599

546 women, 543 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 59%
Arthritis 55%
Chronic kidney disease 44%
Diabetes 38%
Atrial fibrillation 38%
Heart failure 33%
Depression 29%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, regadenoson, 0.1 mg J2785 Office 76 304 $1,751

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 7 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VERQUVO
  • Merck Sharp & Dohme Corporation $59
$59 — —
LEQVIO
  • Novartis Pharmaceuticals Corporation $43
$43 — —
ENTRESTO
  • Novartis Pharmaceuticals Corporation $43
$43 86 —
XARELTO
  • Janssen Pharmaceuticals, Inc $35
$35 104 —
ELIQUIS
  • PFIZER INC. $22
$22 368 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 7 in the dashboard with a free account

Records

475 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record